Description
CJC-1295 DAC Peptide
CJC-1295 is a peptide that appears to function similarly to GHRH, potentially boosting growth hormone levels. DAC is a biochemical complex that may significantly increase the life of the peptide. CJC-1295 & Ipamorelin blend has been studied for its suggested compounded potential. The CJC-1295 peptide is a synthetic 29 amino acid analog of growth hormone-releasing hormone (GHRH). (2)
The hypothalamus is considered by researchers to secrete Growth Hormone-Releasing Hormone (GHRH) and may stimulate Growth Hormone (GH) synthesis and secretion. The amount of GHRH produced appears to depend on metabolic status, sex, and age. GHRH is closely related to sleep promotion and feeding regulation. In addition, the Growth Hormone that depends on GHRH has a metabolic role: it may stimulate protein synthesis and maintain blood glucose within a normal range. It also has growth potential: it may stimulate tissues, including the liver, to secrete growth factors that lead to bone growth. (4) Dysfunctions in GHRH may lead to abnormal growth.
Overview
CJC-1295 is known under many titles: CJC-1295, CJC-1295 with DAC, DAC:GRF, long-acting GHRH analog, and synthetic GHRH analog. Theoretically, as the peptide is considered a releasing factor for growth hormone, CJC-1295 has been studied for its potential role in:
- The reduction of fat mass by using the fat as an energy source. It may lead to an increased muscle mass via promoting the synthesis of proteins.
- Since growth hormone promotes bone growth and improved joint and connective tissue health, CJC-1295 peptide may potentially improve bone mass and reduce injuries.
- Studies have suggested that GHRH supports normalized sleep patterns, potentially this action may be extended to analogues like CJC-1295. (5)
Research and Clinical Studies
CJC-1295 DAC Peptide Mechanism of Action
Researchers conducted two clinical studies in 2006 to examine the action of CJC-1295. The test subjects were between the ages of 21-61 years old. In the first study the CJC-1295 or placebo was presented in one of four ascending concentrations. On the other side, in the second study CJC-1295 was presented two or three times each week. According to the results, after the presentation of CJC-1295, there appeared to be an increase in GH and IGF-I levels (IGF-1: Insulin-like growth factor 1) among the subjects. (7)
In 2006, another group of scientists assessed the GH pulsatility after a single occurrance of CJC-1295. They found out that there appeared to be an increase of about 50% in GH secretion and IGF-I levels after the single presentation of CJC-1295. (8)
Additional animal studies were conducted to evaluate the potential of CJC-1295. An interesting study was conducted using mice presented with the peptide or a placebo. The researchers concluded that giving the mice once-daily CJC-1295 might completely normalize growth. Another finding was that CJC-1295 every 2 or 3 days appeared to produce intermediate results, indicating a probable interval-dependent action. (9)
CJC-1295 DAC Peptide Half-life
In its original form, CJC-1295 uses a technology referred to as Drug Affinity Complex (DAC). (2) Contrary to the GHRH which has a half-life of approximately 7 minutes, CJC-1295 is reported by researchers to exhibit a longer half-life of 6-8 days due to the DAC technology. (10)
CJC-1295 DAC Peptide Ancillary Studies
In 2005, a study began to evaluate the mechanism of action of CJC-1295 in subjects with immunodeficiency virus (HIV) associated with visceral obesity. In this study, the subjects would be presented with CJC-1295 for 3 months and followed by a 6 week follow-up period. However, this study was terminated during the recruitment process, and no related results were posted. (6)
According to a Norwegian study, in 2009 a compound was submitted for analysis to evaluate whether it contained prohibited substances or not. The researchers of the Norwegian Doping Control Laboratory and School of Pharmacy reported that this substance was CJC-1295. In their published article they concluded that “CJC-1295 is a releasing factor for growth hormone“. (2)
CJC-1295 DAC peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.
References:
1. Linder J. The science behind peptides. Plast Surg Nurs. 2012 Apr-Jun;32(2):71-2. doi: 10.1097/PSN.0b013e3182577344. PMID: 22647954.
2. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010 Nov-Dec;2(11-12):647-650. DOI: 10.1002/dta.233.
3. Kastin, A., 2006. Handbook of biologically active peptides. 1st ed. Amsterdam: Academic Press, CHAPTER 93 – Growth Hormone-Releasing Hormone pp.663-671.
4. Vivo.colostate.edu. 2021. Growth Hormone (Somatotropin). (online) Available at: (Accessed 26 April 2021).
5. Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997 Nov;20(11):1038-52. PMID: 9456470.
6. ClinicalTrials.gov, A service of the US National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/show/NCT00267527 (27 June 2010).
7. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.
8. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.
9. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
10. Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016 Jan 2;51(1):73-84. doi: 10.3109/10826084.2015.1082595. Epub 2016 Jan 15. PMID: 26771670.
11. World Anti-Doping Agency. 2021. What is Prohibited. (online) Available at: (Accessed 26 April 2021).
NOTE: These products are all intended for laboratory research use only. CJC 1295 with DAC for sale is not for personal use. Please review and adhere to our Terms and Conditions before ordering.
There is an increasing level of research being performed on peptide blends, in particular CJC 1295 Ipamorelin Blend. To read more about this blend, read our CJC 1295 Ipamorelin Research Benefits blog post.
Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.
